Project Grant R01CA288372
Award Date
12/20/24
Completion Date
11/30/29
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Louisville, KY 40202, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $400,000 to Oncotab, Inc. to develop an optimized targeted radiotherapy for pancreatic ductal adenocarcinoma (PDAC). The project aims to use a tumor-specific antibody, HTAB004, and a tandem single-chain variable fragment (scFv) to target PDAC tumors and deliver alpha and beta particle-emitting radioisotopes. Through a structured design of experiments, the project will evaluate how the...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $627,272 Project Grant (CFDA 93.395 Cancer Treatment Research) to The Johns Hopkins University to optimize the efficacy of CAR T cells against pancreatic tumors. The goal is to engineer self-propelled, tumor-infiltrating CAR T cells using synthetic cytokine receptors (velocity receptors) that enhance CAR T cell migration speed and tumor infiltration. The researchers plan to test the motility and...
This Project Grant award, titled "A NOVEL IMMUNOTHERAPY FOR PANCREATIC CANCER USING MICRO-RNA-29A," was provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) to the University of Miami in the amount of $107,948. The award will support research to determine the contribution of the TNFR2-miR-29a axis to CD8 T cell dysfunction in pancreatic ductal adenocarcinoma (PDAC), with the goal of generating durable T-cell mediated anti-tumor activity. The...
The National Cancer Institute (NCI) awarded a 5-year, $654,197 Project Grant (CFDA 93.396 - Cancer Biology Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on pancreatic ductal adenocarcinoma (PDAC). The key objectives are to: Define the molecular subtypes of PDAC that respond to standard-of-care chemotherapies like FOLFIRINOX and gemcitabine + Abraxane. Elucidate how different stromal subtypes within patient-derived...
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...
The National Cancer Institute (NCI) awarded a $110,550 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Trustees of the University of Pennsylvania on September 10, 2025. The grant supports research into the "Mechanisms of Lymphatic Metastasis in Pancreatic Ductal Adenocarcinoma". The project aims to investigate how regulatory T cells in lymph nodes suppress the anti-tumor immune response, enabling early lymph node metastasis. Specifically, the research will...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
This Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) aims to advance a local controlled release platform for intratumoral delivery of hyaluronidase to improve the efficacy of systemically administered drugs for pancreatic ductal adenocarcinomas (PDAC). The award totals $599,474 and will fund a 5-year project from Sep 1, 2024 to Aug 31, 2029. The key products and services to be delivered through this grant include: 1) using...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $674,275 in funding to Marker Therapeutics Inc., a small disadvantaged biotechnology company, to conduct a Phase 1 clinical study evaluating the safety and efficacy of their MT-601 multi-tumor associated antigen-specific T-cell therapy in patients with metastatic pancreatic cancer. The study aims to assess the clinical outcomes of combining MT-601 with frontline FOLFIRINOX chemotherapy,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is supporting research conducted by the University of Texas MD Anderson Cancer Center to investigate the role of sulfatide metabolism in the development and progression of pancreatic cancer precursor lesions. The $616,495 grant, awarded on March 1, 2025, has a 5-year project period ending on February 28, 2030. The key objectives of this research are to: 1) define the biological functions...